CRDF
Price:
$3.74
Market Cap:
$174.10M
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, ...[Read more]
Industry
Biotechnology
IPO Date
2004-07-27
Stock Exchange
NASDAQ
Ticker
CRDF
According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 150.44M. This represents a change of 49.19% compared to the average of 100.84M of the last 4 quarters.
The mean historical Enterprise Value of Cardiff Oncology, Inc. over the last ten years is 76.54M. The current 150.44M Enterprise Value has changed 19.56% with respect to the historical average. Over the past ten years (40 quarters), CRDF's Enterprise Value was at its highest in in the March 2021 quarter at 330.12M. The Enterprise Value was at its lowest in in the June 2018 quarter at -12769882.72.
Average
76.54M
Median
47.01M
Minimum
-4043043.50
Maximum
245.42M
Discovering the peaks and valleys of Cardiff Oncology, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 31.22%
Maximum Annual Enterprise Value = 245.42M
Minimum Annual Increase = -23245.43%
Minimum Annual Enterprise Value = -4043043.50
Year | Enterprise Value | Change |
---|---|---|
2023 | 46.62M | -1.67% |
2022 | 47.41M | -79.00% |
2021 | 225.75M | -8.02% |
2020 | 245.42M | -23245.43% |
2019 | -1060356.56 | -73.77% |
2018 | -4043043.50 | -204.83% |
2017 | 3.86M | -90.82% |
2016 | 42.01M | -53.56% |
2015 | 90.47M | 31.22% |
2014 | 68.95M | -3.95% |
The current Enterprise Value of Cardiff Oncology, Inc. (CRDF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
106.59M
5-year avg
112.83M
10-year avg
76.54M
Cardiff Oncology, Inc.’s Enterprise Value is greater than Reviva Pharmaceuticals Holdings, Inc. (28.64M), greater than eFFECTOR Therapeutics, Inc. (3.64M), greater than PDS Biotechnology Corporation (85.57M), greater than Navidea Biopharmaceuticals, Inc. (-2555017.00), greater than Reviva Pharmaceuticals Holdings, Inc. (28.64M), greater than Eyenovia, Inc. (57.71M), greater than Cognition Therapeutics, Inc. (-8869924.00), greater than TransCode Therapeutics, Inc. (5.76M), less than Kodiak Sciences Inc. (161.73M), greater than SELLAS Life Sciences Group, Inc. (66.71M), greater than NLS Pharmaceutics AG (12.01M), less than Mereo BioPharma Group plc (535.33M), greater than Aravive, Inc. (-3158140.00), less than Day One Biopharmaceuticals, Inc. (1.07B), greater than IN8bio, Inc. (9.94M), greater than Cue Biopharma, Inc. (70.94M), greater than Lantern Pharma Inc. (22.55M), less than Gracell Biotechnologies Inc. (5.47B), less than Cullinan Oncology, Inc. (810.70M), greater than Bolt Biotherapeutics, Inc. (38.25M), greater than Lyra Therapeutics, Inc. (22.05M), less than Autolus Therapeutics plc (470.32M),
Company | Enterprise Value | Market cap |
---|---|---|
28.64M | $33.39M | |
3.64M | $1.88K | |
85.57M | $118.93M | |
-2555017.00 | $50.04K | |
28.64M | $36.43M | |
57.71M | $44.32M | |
-8869924.00 | $19.04M | |
5.76M | $8.89M | |
161.73M | $205.20M | |
66.71M | $75.27M | |
12.01M | $10.85M | |
535.33M | $616.59M | |
-3158140.00 | $2.95M | |
1.07B | $1.49B | |
9.94M | $14.26M | |
70.94M | $89.71M | |
22.55M | $35.31M | |
5.47B | $989.87M | |
810.70M | $922.99M | |
38.25M | $25.56M | |
22.05M | $17.21M | |
470.32M | $888.59M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cardiff Oncology, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Cardiff Oncology, Inc. (CRDF)?
What is the 3-year average Enterprise Value for Cardiff Oncology, Inc. (CRDF)?
What is the 5-year average Enterprise Value for Cardiff Oncology, Inc. (CRDF)?
How does the current Enterprise Value for Cardiff Oncology, Inc. (CRDF) compare to its historical average?